Similar to CD133, CD166+ prostate cancer cells have stronger ability of regeneration and proliferation and can produce primitive tumor heterogeneity in xenografts, while knockout of CD166 could inhibit tumor growth 29. This evidence concerns the gene ALCAM and neoplasm.